ODP124 Sickle Cell Bone Disease and Response to Intravenous Bisphosphonates in Children
R. Todd Alexander(University of Alberta), Rose Girgis(University of Alberta Hospital), Nathalie Alos(Centre Hospitalier Universitaire Sainte-Justine), Patricia Diaz Escagedo(Centre Hospitalier Universitaire Sainte-Justine), Jacob L. Jaremko(University of Alberta), Marika Pagé, Victor N. Konji, Ewurabena Simpson(University of Ottawa), Chelsey Grimbly(University of Alberta), Leanne M. Ward(Children's Hospital of Eastern Ontario), Yves Pastore(Centre Hospitalier Universitaire Sainte-Justine), Aisha Bruce(University of Alberta), Marie‐Eve Robinson(University of Ottawa)
Cited by 0
Related Papers
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
|The Lancet|2019|375
Calcium and phosphate homeostasis: Concerted interplay of new regulators
|Annals of Medicine|2008|262
Traditional and emerging roles for the SLC9 Na+/H+ exchangers
|Pflügers Archiv - European Journal of Physiology|2013|187